Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2026 · 10-Q
Revenue$3.74M$3.74M+36.5% vs Q1 2025 Net Income-$15.20M-$15.20MN/M vs Q1 2025 EPS Diluted-$3.76-$3.76N/M vs Q1 2025 Operating Income-$13,818,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,887,000N/M Margins · derivedOperating margin-369.7%+175.1 pt vs Q1 2025
Net margin-406.6%
ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end